Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
No biomarker
Cancer:
Burkitt Lymphoma
Drug:
methotrexate
(
THF dehydrogenase inhibitor
,
Dihydrofolic acid reductase inhibitor
)
Regimen:
(cytarabine + etoposide IV + ifosfamide + Rituxan (rituximab))
Direction:
Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
NCCN
Excerpt:
Burkitt lymphoma: suggested treatment regimens…second-line therapy…other recommended regimens…RIVAC (rituximab, ifosfamide, cytarabine, etoposide); intrathecal methotrexate if have not received previously
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login